Therapeutic status quo in patients with relapsing-remitting multiple sclerosis: a sign of poor self-perception of their clinical status? by Saposnik, Gustavo et al.








Therapeutic status quo in patients with relapsing-remitting multiple
sclerosis: a sign of poor self-perception of their clinical status?
Saposnik, Gustavo ; Sotoca, Javier ; Sempere, Ángel P ; Candeliere-Merlicco, Antonio ; Díaz-Abós,
Paola ; Tobler, Philippe N ; Terzaghi, Maria ; Maurino, Jorge
Abstract: Background Status quo (SQ) bias is defined as patient´s tendency to continue taking a pre-
viously selected but inferior therapeutic option. Objective To assess the presence of SQ bias and its
associated factors in patients with relapsing-remitting multiple sclerosis (RRMS). Methods A multicen-
ter, non-interventional study involving 211 patients with RRMS was conducted. Participants answered
questions regarding risk preferences and management of simulated MS case-scenarios. The SymptoM-
Screen (SMSS) questionnaire was used to assess the perception of severity from the patients´ perspective.
SQ bias was defined as patients’ preference to maintain the current treatment despite evidence of disease
activity. Mixed linear models adjusting for clustering assessed the association of candidate predictors
with the outcome of interest. Results The mean age (SD) was 39.1 (9.5) years and 70.6% were women.
SQ bias was observed in 74.4% (n=161) participants. Univariate analysis showed that SMSS score was
associated with SQ bias (OR 1.04; 95% CI 1.01-1.07). Mixed linear regression models suggest that for ev-
ery point increase in SMSS, there was a 4% increase in the likelihood of SQ bias (฀ 0.04; 95%CI 0.015-0.06;
p<0.002). Among the different symptomatic dimensions included in the SMSS, only vision impairment
(฀ 0.32; 95%CI 0.05-0.50) and depression (฀ 0.29; 95%CI 0.006-0.58) remained associated with SQ bias in
the multivariate analysis. There was no association between participants’ risk preferences and SQ bias.
Conclusions Unwillingness to pursue treatments that are more effective is a common phenomenon affect-
ing over 7 out of 10 patients with RRMS. This phenomenon appears to be driven by patients’ negative
self-perception of their clinical status.
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A B S T R A C T
Background: Status quo (SQ) bias is defined as patient´s tendency to continue taking a previously selected but
inferior therapeutic option.
Objective: To assess the presence of SQ bias and its associated factors in patients with relapsing-remitting
multiple sclerosis (RRMS).
Methods: Amulticenter, non-interventional study involving 211 patients with RRMS was conducted. Participants
answered questions regarding risk preferences and management of simulated MS case-scenarios. The
SymptoMScreen (SMSS) questionnaire was used to assess the perception of severity from the patients´ per-
spective. SQ bias was defined as patients’ preference to maintain the current treatment despite evidence of
disease activity. Mixed linear models adjusting for clustering assessed the association of candidate predictors
with the outcome of interest.
Results: The mean age (SD) was 39.1 (9.5) years and 70.6% were women. SQ bias was observed in 74.4%
(n=161) participants. Univariate analysis showed that SMSS score was associated with SQ bias (OR 1.04; 95%
CI 1.01-1.07). Mixed linear regression models suggest that for every point increase in SMSS, there was a 4%
increase in the likelihood of SQ bias (β 0.04; 95%CI 0.015-0.06; p<0.002). Among the different symptomatic
dimensions included in the SMSS, only vision impairment (β 0.32; 95%CI 0.05-0.50) and depression (β 0.29;
95%CI 0.006-0.58) remained associated with SQ bias in the multivariate analysis. There was no association
between participants’ risk preferences and SQ bias.
Conclusions: Unwillingness to pursue treatments that are more effective is a common phenomenon affecting over
7 out of 10 patients with RRMS. This phenomenon appears to be driven by patients’ negative self-perception of
their clinical status.
Multiple sclerosis (MS) is a chronic autoimmune neurological dis-
order with a negative impact on patients, their families, and society
(Kobelt et al., 2017; García-Domínguez et al., 2019). In recent years, the
approval of several new disease modifying therapies (DMT) with dif-
ferent efficacy-risk profiles has added more complexity to the clinical
management of MS (Montalban et al., 2018; Saposnik and
Montalban, 2018). In this context, there has been a growing interest in
patient's views under the paradigm of patient-centered outcomes
(Khurana et al., 2017; D´Amico et al., 2019). Establishing treatment
goals together with patients is still an unmet need (Yeandle et al., 2018;
Day et al., 2018). Shared decision-making emerged as a potential so-
lution, but is hindered by multiple factors, such as physician-patient
communication, knowledge gaps regarding therapeutic alternatives, or
subjective patient factors not shared with their MS specialists
(O´Conor et al., 2007; Kachuck et al., 2011).
Therapeutic inertia (TI) is defined as physicians’ lack of treatment
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initiation or escalation when treatment goals are unmet (e.g. disease
activity by accepted clinical and/or radiological parameters)
(Saposnik and Montalban, 2018). TI is recognized as an important
physician factor leading to suboptimal care in MS in many countries
(Saposnik and Montalban, 2018; Almusalam et al., 2019). On the other
hand, status quo (SQ) bias is defined as patients´ preference to maintain
the current treatment despite clinical and radiological evidence of
disease activity (Suri et al., 2013). SQ bias denotes a patient attribute in
a similar way as TI is related to physicians. Limited information is
available regarding the prevalence of SQ bias and its determinants in
patients with MS.
We hypothesized that some individual patient characteristics (e.g.
number of relapses in the last year, current disability, subjective per-
ception of symptoms) are associated with SQ bias in MS patients and
that SQ bias may be a common phenomenon. In the present study, we
evaluated the presence of SQ bias and its associated factors in a po-
pulation of patients with relapsing-remitting multiple sclerosis (RRMS).
1. Methods
We conducted a non-interventional, cross-sectional study involving
patients with RRMS receiving care in 17 MS centers in Spain between
December 4, 2018 and March 5, 2019 (PERCEPTIONS-MS study). Key
eligibility criteria included age 18 years and older, a diagnosis of RRMS
according to the 2010 revised McDonald criteria, and an Expanded
Disability Status Scale (EDSS) score range from 0 to 5.0 (Polman et al.,
2011; Kurtzke et al., 1983). Written informed consent was obtained
from all subjects. The study was approved by the institutional review
board of the Hospital Universitari Clínic i Provincial de Barcelona.
1.1. Study flow
Participants first answered questions regarding demographic data
and perception of symptom severity. Investigators collected clinical
characteristics and assessed patients´ cognition. Patients then watched
a segment of a publicly available tutorial about MS diagnosis and
treatment (https://youtu.be/m37WzLseWUI). Participants were in-
formed about treatment options, presented as a menu of non-branded
hypothetical options (labelled as Treatments A-F) with different effi-
cacy and safety profiles mimicking the currently available disease-
modifying agents (Table 1) (Li et al., 2019; Lucchetta et al., 2019). The
tutorial and menu of treatment options explained the accepted criteria
used by MS specialists to switch or escalate therapies. A case-vignette
was used as an example to assess patient understanding of the treatment
escalation criteria.
Finally, patients completed behavioral experiments to assess risk
preferences and were asked to choose their treatment preference in
twelve simulated MS case-scenarios or case-vignettes (eight case-sce-
narios were focused on SQ bias). Simulated case-scenarios were ori-
ginally designed by our research team and MS experts (GS, JM, APS,
EHML) derived from the most common situations experienced by pa-
tients in clinical practice. The study (simulated case-scenarios, treat-
ment options and tutorial) were conducted in Spanish, the mother
tongue of patients. Case-scenarios are shown in Appendix. Further de-
tails of the study flow are presented in Fig. 1.
The SymptoMScreen (SMSS) questionnaire was used to assess pa-
tients’ self-perception of symptom severity (Green et al., 2017; Meca-
Lallana et al., 2020). Cognitive performance was assessed using the
Symbol Digit Modalities Test (SDMT) (Benedict et al., 2017). We
evaluated risk preferences by identifying the safe amount for which a
participant is indifferent to a 50/50 gamble of winning an amount X or
0 euros against a safe option (Christopoulos et al., 2009; Saposnik et al.,
2016). This indifference amount, called certainty equivalent, reflects
the participant-specific value associated with the risky option. For ex-
ample, participants were asked what would be the minimum amount of
money that they would prefer obtaining for sure instead of the equi-
probable gamble of winning 400 or 0 euros. We also used the German
Socio-Economic Panel (SOEP), a validated survey that evaluates will-
ingness to take risks in different domains of daily life (Wagner et al.,
2007). Further details of these tests are published elsewhere
(Saposnik et al., 2016).
1.2. Outcome measures
SQ bias was defined as patients’ preference to maintain the current
MS treatment in the simulated case-scenarios (e.g. first-line injectable
therapies) despite new clinical relapses and radiological evidence of
disease activity. We created a SQ score with the number of case-sce-
narios that met the criteria for SQ bias over the total number of sce-
narios presented. SQ bias was also analyzed as a categorical variable
dichotomized as SQ bias present vs. absent. A secondary outcome
measure included SQ4, defined as SQ bias in 4 or more case-scenarios to
assess the consistency of the association with potential covariates.
1.3. Statistical analysis
We used non-parametric tests (Wilcoxon rank-sum and Kruskal-
Wallis test) to compare continuous and categorical variables between
Table 1
Hypothetical treatment options
Efficacy (annualized relapse rate
reduction)
Frequent, but mild side effects (20-30%) Rare, but severe side effects (1-5%)
Treatment A




SC 3 times a week Approximately 30% Skin reaction at the injection site Abscess, inflammation of skin/soft tissue
underneath
Treatment C
Once-daily oral Approximately 30% Gastrointestinal symptoms Liver injury
Treatment D
Twice-daily oral Approximately 50% Gastrointestinal symptoms, flushing Severe infections
Treatment E
Once-daily oral Approximately 50% Slow heart rate (bradycardia) Severe infections
Treatment F
IV 5 consecutive days (first year) + 3 consecutive
days (second year)
Approximately 80% Thyroid disorders Severe infections, autoimmune disorders
Treatment G
IV monthly Approximately 80% - Severe infections
IM: intramuscular; IV: intravenous; SC: subcutaneous.
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groups. SMSS was primarily analyzed as a continuous variable. We also
divided SMSS in quartiles (Q1: no symptoms at all to mild symptoms,
Q4: severe symptoms) to determine the presence of a gradient effect on
the outcomes of interest. Mixed linear models adjusting for clustering
assessed the association of candidate predictors with the outcome of
interest. Multilevel mixed-effects logistic regression adjusting for clus-
tering assessed the association of candidate predictors with the outcome
of interest (SQ bias present vs. absent and SQ4). For multivariate ana-
lysis of individual responses, we included a random effect of participant
(211 levels) and a random effect of scenario (8 levels), because re-
sponses are cross-classified by participant and scenario. The aim of this
analysis was to evaluate the contribution of individual-specific vari-
ables to the variation of SQ bias. Variables for adjustment were selected
a priori based on previous studies on factors influencing treatment
decisions, including participant's age, sex, disease duration, total
number of relapses, months from last relapse, EDSS score, SMSS score,
SMDT score, number of DMT, and risk preferences (Lynd et al., 2016;
Visser et al., 2020; Saposnik et al., 2017a; Saposnik et al., 2017b). There
was no data imputation.
A sensitivity analysis was conducted by adding living status (alone
vs. other- partner or caregiver) and marital status (single, married,
other). We also analyzed the depression subscore of the SMSS scale by
SQ bias. C-statistics was used to assess discrimination ability of the
models, whereas the roccomp command was used to compare differ-
ences between regression models after adjustment. All tests were 2-
tailed, and p-values <0.05 were considered significant. We used STATA
13 (College Station, TX: StataCorp LP) to conduct all analyses.
2. Results
From a total of 218 participants who met the inclusion criteria, 211
(96.8%) patients completed the study. Completed clinical data as pro-
vided by the treating physician was available for 161 (76.3%) partici-
pants, whereas in the remaining 50 participants their responses could
not be properly matched with objective clinical information reported by
their neurologist. The mean age (SD) was 39.1 (9.5) years and 70.6%
were women. The main demographic and clinical characteristics of the
sample are shown in Table 2.
The mean SMSS score (SD) was 16.5 (14) [(median score: 13, IQR
[4-27]).
The mean SQ bias score (SD) was 2.82 (2.0). Overall, SQ bias was
present in at least one case-scenario in 74.4% (157/211) of participants.
Thirty-five percent (n=74) of participants were unwilling to switch
therapy in half or more of the presented scenarios (SQ4) despite being
informed of the high risk of disease progression. The analysis of in-
dividual responses showed that 614/2110 (29.1%) met the SQ bias
criteria. There was a higher number of individual responses meeting the
SQ criteria for patients with higher SMSS scores (p-value: 0.02). The
distribution of SQ bias by quartiles of SMSS groups is shown in Fig. 2
(Panel A). There was no association between prior exposure to DMT and
SQ bias (Fig. 2, panel B). There was also no association between par-
ticipants’ risk preference and SOEP with SQ bias (p-values of 0.44 and
0.51, respectively). There were no significant differences in cognitive
function (mean SDMT 51.4 vs 54.5; p=0.38) and depression (10.2% vs.
5.6%; p=0.31) between participants with and without SQ bias.
The univariate analysis showed that SMSS score was associated with
SQ bias (unadjusted OR 1.05; 95% CI 1.02-1.07). Similar findings were
observed after adjustment for age, sex, education, living status, disease
duration, total number of relapses, EDSS score, and number of previous
Fig. 1. Study flow
EDSS: Expanded Disability Status Scale; MS: multiple sclerosis; SOEP: Socio-economic Panel; SQ: status quo.
Table 2
Demographic and clinical characteristics
Total (n=211)
Age (years), mean± SD 39.1± 9.5





Living status, n (%)
Alone 27 (12.8)
With a partner 122 (57.8)
With family members 55 (26.1)
Other 7 (33)
Time since diagnosis (years), mean± SD 6.64± 4.45
Number of relapses since diagnosis, mean± SD 3.5± 3.7
Number of relapses in the last year, mean± SD 0.4± 0.7
Number of DMTs since diagnosis, mean± SD 2.13± 1.16
EDSS median (interquartile range) 2.0 (1.0-2.5)
SDMT score, mean± SD 52.2± 20.5
Risk preference, mean± SD 246.0± 107
SOEP, mean± SD 28.3± 14.5
SymptomMScreen score, mean±SD 16.5± 13.9
DMT: disease-modifying therapy; EDSS: Expanded Disability Status Scale; MS:
multiple sclerosis; SDMT: Symbol Digit Modalities Test; SOEP: Socio-economic
Panel; SD: standard deviation; SQ: status quo.
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MS treatments (adjusted OR 1.04; 95% CI 1.01-1.07) (Table 3, Fig. 3,
and Appendix). Mixed linear regression models suggest that for every
point increase in SMSS, there was a 4% increase in the likelihood of SQ
bias (β coefficient 0.04; 95%CI 0.015-0.06; p<0.002) (Appendix).
Other outcome measures are summarized in Table 3. The number of
previous exposures to DMTs was associated with SQ bias score
(p=0.032), but did not reach significance in the multilevel mixed-ef-
fects logistic regression (Appendix). SQ bias was more common among
simulated-case-scenarios who were already receiving treatment com-
pared to those who were treatment naïve (31.3% vs 12.8%; McNemar
test p-value<0.0001). Our results were also consistent in the sensitivity
analysis after adding living status (alone vs. partner/caregiver) or
marital status to the models. None of those variables was significant in
any of the models (data not shown).
Finally, we attempted to specify which component of the SMSS
score was associated with SQ bias. Among the different symptomatic
dimensions included in the SMSS, spasticity, bladder control, vision,
cognition, depression, and anxiety were associated with SQ bias in the
univariate analysis. The multivariate analysis revealed that only vision
impairment (β coefficient 0.32; 95%CI 0.05-0.50) and depression (β
coefficient 0.29; 95%CI 0.006-0.58) remained associated with SQ bias.
The adjusted models with SMSS showed better performance than the
models containing depression and vision impairment (c-statistics for
SQ: 0.767 vs 0.685; p=0.015; c-statistics for SQ bias score: 0.726 vs
0.643; p=0.006).
3. Discussion
Most neurologists traditionally make therapeutic decisions in MS
based on the presence of clinical relapses and MRI findings of disease
activity (e.g. gadolinium-enhancing T1 lesions, new or enlarging hy-
perintense T2 lesions) (Montalban et al., 2018). Patients’ perceptions of
their functional status and beliefs about their medical condition and
how they may influence therapeutic decisions have been inadequately
studied (Visser et al., 2020). Our study showed that an inferior ther-
apeutic option was preferred by over 70% of participants with RRMS
when treatment escalation was warranted according to best practice
recommendations. The presence of SQ bias in at least 50% or more of
simulated case-scenarios was observed in over one-third of participants.
Patients’ individual perception of MS impact was the single
Fig. 2. Status quo bias (SQ) by quartiles of SMSS (Panel A) and DMT exposure (Panel B)
DMT: disease-modifying therapy; SMSS: SymptoMScreen questionnaire.
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independent predictor of SQ bias. Our findings are even more surprising
when considering the apparently benign characteristics of our study
population (median EDSS 2 [IQR 1.0-2.5], with a low average number
of relapses in the last year (median 0.4, IQR [0-1]) and a long elapsed
time since the last relapse [mean 22.6 (12.9) months].
Given the increasing amount of treatments available, patients play a
more important role in shared decisions (either treatment initiation or
escalation) with their neurologist (Arroyo et al., 2017). Individual
thoughts or negative perceptions towards some agents may not always
be openly shared with healthcare professionals, impacting on ther-
apeutic decisions and adherence (Colligan et al., 2017; Wilski et al.,
2019). Other studies has reported on the relevance of the development
of patients’ awareness and self-regulation about their MS trajectory and
the role of the treating physician in communicating the prognosis
(Colligan et al., 2017).
In this context, there are external and internal factors influencing
patients´ therapeutic choices (Saposnik and Montalban, 2018). Among
the external factors that have been classically related to treatment de-
cisions, the main ones are age, time from MS diagnosis, disability stage
or number of previous treatments used (Saposnik and
Montalban, 2018). Internal factors include depression, subjective dis-
ability perception or having higher risk-seeking personality
(Saposnik and Montalban, 2018). Wilski et al showed that a worse self-
perception of physical condition and illness in MS patients was asso-
ciated with beliefs of negative treatment efficacy (Wilski et al., 2019).
Depression also emerged as one of the cardinal symptoms that corre-
lated with poor self-rated health, but not vision impairment
(Green et al., 2017). Consistent with other studies, patients are more
fearful about the side effects of the medication than impact of the
disease itself, and this is enhanced among those with an overly negative
Table 3
Multivariate analysis for the primary and secondary outcome measures
Outcome measures Mild perception of
symptoms (n=107)








SQ bias score, mean (± SD) 2.63 (1.95) 3.00 (2.03) (0.37) 0.04 (0.015; 0.06); p=0.002 †
SQ4 (SQ bias in 4 or more case-scenarios), n
(%)
30 (28.0) 44 (42.3) (14.3) 1.05 (1.02; 10.8); p<0.001 *
SQ bias (present vs. absent) in at least 1 case
scenario, n (%)
76 (71.0) 81 (77.9) (6.9) 1.04 (1.01; 1.07); p<0.001 *
Individual responses n=1070 n=1040
SQ bias, mean (± SD) 26.2 (22.3) 30.0 (28.0) (3.8) 0.03 (0.003; 0.07); p=0.03 ‡
SQ4 (SQ bias in 4 or more case-scenarios), n
(%)
155/1070 (14.5) 216/1040 (20.8) (6.3) 1.05 (1.02; 1.08); p<0.001 ‡
EDSS: Expanded Disability Status Scale; SD: standard deviation; SQ: status quo.
Mild symptoms defined as SMSS (Q1+Q2), whereas moderate to severe self-perception of symptoms was defined by Q3+Q4 of SMSS.
All models adjusted for age, EDSS, time since MS diagnosis, number of relapses, number of relapses in the last year, number of DMTs, risk preference, and SMSS as a
continuous variable).
⁎ Derived from multivariate logistic regression analysis with SQ4 and SQ bias (present vs. absent) as dependent variable. C-statistics for SQ4: 0.71 and for SQ bias:
0.72
† Derived from linear regression models and expressed in β coefficients (95%CI) with SQ bias score as dependent variable. SQ bias scores were significantly higher
among participants with higher SMSS values after adjustment for the pre-specified variables.
‡ Derived from multilevel mixed effects models expressed as OR (95%CI) for binary outcomes (SQ4) and β coefficients (95%CI) for the SQ bias score.
Fig. 3. Observed and predicted probability of Status quo bias in relation to patient's perception of MS severity assessed by SymptoMScreen
SMSS: SymptoMScreen questionnaire.
G. Saposnik, et al. Multiple Sclerosis and Related Disorders 45 (2020) 102354
5
perception of their functional status (Visser et al., 2020; Arroyo et al.,
2017). Patients’ beliefs may lead to erroneous prognosis forecasting
leading to poorer quality of life and increasing SQ bias (Dennison et al.,
2018). For example, patients’ belief of MS being incurable can dominate
attitudes and prevent escalation or attempts to optimize treatment.
Treatment decisions in MS are dynamic and subjectively influenced
by patients’ experiences of illness and healthcare (Eskyte et al., 2019).
Our study is in line with our previous research on therapeutic inertia
among treating neurologists suggesting a general knowledge-to-action
gap affecting both sides of the physician-patient relationship
(Saposnik et al., 2017a). Indeed, this relationship in patients could be
affected by cognitive (e.g., pessimistic beliefs about symptom relief and
preventing disability progression), emotional (e.g., increased depres-
sion/lower mood, fear of side effects) and motivational (e.g., increased
apathy/reduced goal directed action) components, with each leading to
knowledge-to-action gaps (Eskyte et al., 2019; Wilski et al., 2019;
Yalachkov et al., 2019). We may speculate that patients´ negative
perception of their own clinical status (and perhaps a sense of help-
lessness toward the future) is one of the factors that may lead to the SQ
bias (Joiner et al., 2001). This feeling of hopelessness is difficult to
assess in routine clinical practice, which leads to gaps in managing the
patient's expectations and advancing treatment when warranted by best
practice recommendations.
Our study has several limitations that deserve mention. First, our
study population may not be representative of the entire spectrum of
RRMS patients (e.g. EDSS >5) as the great majority of participants had
an EDSS lower than 3. Second, we cannot completely rule out the
possibility that SQ bias is influenced by other factors that have been
included in this study (e.g. type of DMT characteristics or other un-
measured confounders). Third, the lack of information on the treating
neurologist (e.g., presence of therapeutic inertia) may have influenced
patient´s decisions and SQ bias. In addition, we do not have information
about what the treating neurologist would do or recommend in the
simulated case-scenarios presented to the study participants, since our
aim was to assess only patients with RRMS. Other factors that may
attenuate this criticism include results from a recent review showing
that contextual factors, patients’ preferences and beliefs in everyday life
are equally or even more important than clinical measures when
making treatment decisions (Eskyte et al., 2019). Fourth, given the
small number and differences between simulated case-scenarios, the
comparison of other characteristics associated with SQ bias could not be
done. Fifth, some variables provided by the treating physician were
missing in 20-24% of participants due to a failure with reporting the
matching number. However, the baseline characteristics of our study
are similar to other survey-based and cohort studies reported in other
countries (Fitzgerald et al., 2019). Despite these limitations, our study
revealed critical insights into how patients’ beliefs and subjective per-
ception of symptom severity influence their willingness to accept
treatment escalation, thus limiting the use of more efficacious ther-
apeutic choices when recommended by best practice guidelines. One in
three patients with mild MS are not willing to switch to agents that offer
more protection in more than 50% of the simulated scenarios pre-
sented. Similarly, one in five patients makes suboptimal therapeutic
choices despite having a low number of relapses, a low level of dis-
ability, and not having symptoms of depression.
4. Conclusion
The landscape of MS treatment is changing rapidly. As different
disease-modifying therapies are available, they bring new opportunities
to achieve better clinical outcomes. However, our study found that
status quo bias affected 7 out of 10 patients with RRMS. This phe-
nomenon appears to be driven by patients’ negative self-perception of
their clinical status.
Further studies are needed to determine the magnitude of the cog-
nitive, emotional and behavioral components leading to status quo bias
among RRMS patients.
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